|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ISRCTN |
|
Last refreshed on:
|
13 January 2015 |
|
Main ID: |
ISRCTN83050762 |
|
Date of registration:
|
13/01/2005 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Quetiapine augmentation of a serotonin reuptake inhibitor in treatment resistant obsessive-compulsive disorder: a multi-site, placebo-controlled study
|
|
Scientific title:
|
|
|
Date of first enrolment:
|
01/05/2002 |
|
Target sample size:
|
42 |
|
Recruitment status: |
Completed |
|
URL:
|
http://isrctn.com/ISRCTN83050762 |
|
Study type:
|
Interventional |
|
Study design:
|
Randomised controlled trial (Treatment)
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Canada
|
South Africa
| | | | | | |
|
Contacts
|
|
Name:
|
Dan J
Stein |
|
Address:
|
MRC Research Unit on Anxiety Disorders
Department of Psychiatry
University of Stellenbosch
7505
Cape Town
South Africa |
|
Telephone:
|
+27 (0)21 938 9161 |
|
Email:
|
djs2@sun.ac.za |
|
Affiliation:
|
|
|
|
Name:
|
|
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
|
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria: Subjects with obsessive-compulsive disorder who failed at least one trial (12 weeks duration, of which six weeks at maximum tolerated dose) of a serotonin reuptake inhibitor.
Exclusion criteria: Not provided at time of registration
Age minimum:
Age maximum:
Gender:
Not Specified
|
|
Health Condition(s) or Problem(s) studied
|
Obsessive-compulsive disorder
Mental and Behavioural Disorders
Obsessive-compulsive disorder
|
|
Intervention(s)
|
|
Placebo-controlled, double-blind, flexible-dose augmentation with quetiapine of a serotonin reuptake inhibitor maintaned at the stable maximum tolerated dose.
|
|
Primary Outcome(s)
|
|
Not provided at time of registration.
|
|
Secondary Outcome(s)
|
|
Not provided at time of registration.
|
|
Secondary ID(s)
|
|
5077IL/9009
|
|
Source(s) of Monetary Support
|
|
AstraZeneca Pharmaceuticals (South Africa)
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|